Zai Lab (NASDAQ:ZLAB) Shares Cross Above 50 Day Moving Average – Should You Sell?

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $24.62 and traded as high as $25.99. Zai Lab shares last traded at $25.48, with a volume of 1,894,936 shares.

Trending Headlines about Zai Lab

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a third-quarter loss of $0.41 per ADS, narrower than analysts’ expected loss of about $0.59. Revenue of $108.21 million also slightly exceeded the $107.90 million estimate, providing a near-term earnings surprise. Earnings Flash
• Positive Sentiment: Investors are also looking toward the pipeline: coverage highlighted the possibility of Zai Lab’s first U.S. drug filing and described 2027 as a pivotal year. Progress toward internally developed medicines could provide future growth catalysts, though outcomes remain uncertain. Zai Lab Q3 2026: Loss Narrows 27%, Pipeline Eyes First US Drug Filing UBS on Q3 performance and 2027
• Neutral Sentiment: UBS said third-quarter performance met expectations, framing the main investment focus as execution on the milestones ahead rather than a major change in near-term results. UBS analysis
• Negative Sentiment: Some earnings coverage said revenue declined and the reported quarterly loss widened, tempering the favorable comparison with analyst estimates. Sustained revenue growth and progress through the pipeline remain important to the outlook. Zai Lab Q3 Loss Widens, Revenue Declines

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ZLAB shares. Citigroup upped their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Wall Street Zen raised Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a research report on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Zai Lab Trading Up 12.7%

The firm has a market cap of $2.90 billion, a PE ratio of -14.23 and a beta of 0.77. The business has a fifty day moving average price of $24.62 and a 200 day moving average price of $21.06.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. The business had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million. On average, research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zai Lab news, Director William Lis sold 8,506 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares in the company, valued at approximately $1,048,275. This trade represents a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 9,385 shares of company stock worth $235,145 in the last ninety days. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zai Lab in the third quarter valued at about $62,000. Nykredit A S acquired a new stake in shares of Zai Lab during the second quarter worth about $79,000. China Universal Asset Management Co. Ltd. acquired a new position in Zai Lab in the 3rd quarter worth $211,000. WealthPlan Investment Management LLC purchased a new position in Zai Lab during the 3rd quarter worth approximately $969,000. Finally, Headlands Technologies LLC grew its holdings in shares of Zai Lab by 142.0% in the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after purchasing an additional 39,901 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.